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Abstract
Background: Cancer cells display widespread changes in DNA methylation that may lead to
genetic instability by global hypomethylation and aberrant silencing of tumor suppressor genes by
focal hypermethylation. In turn, altered DNA methylation patterns have been used to identify
putative tumor suppressor genes.
Methods: In a methylation screening approach, we identified ECRG4 as a differentially methylated
gene. We analyzed different cancer cells for ECRG4 promoter methylation by COBRA and bisulfite
sequencing. Gene expression analysis was carried out by semi-quantitative RT-PCR. The ECRG4
coding region was cloned and transfected into colorectal carcinoma cells. Cell growth was assessed
by MTT and BrdU assays. ECRG4 localization was analyzed by fluorescence microscopy and
Western blotting after transfection of an ECRG4-eGFP fusion gene.
Results: We found a high frequency of ECRG4 promoter methylation in various cancer cell lines.
Remarkably, aberrant methylation of ECRG4 was also found in primary human tumor tissues,
including samples from colorectal carcinoma and from malignant gliomas. ECRG4 hypermethylation
associated strongly with transcriptional silencing and its expression could be re-activated in vitro by
demethylating treatment with 5-aza-2'-deoxycytidine. Overexpression of ECRG4  in colorectal
carcinoma cells led to a significant decrease in cell growth. In transfected cells, ECRG4 protein was
detectable within the Golgi secretion machinery as well as in the culture medium.
Conclusions: ECRG4 is silenced via promoter hypermethylation in different types of human cancer
cells. Its gene product may act as inhibitor of cell proliferation in colorectal carcinoma cells and may
play a role as extracellular signaling molecule.
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Background
Genetic and epigenetic events work in concert to trans-
form a normal cell into a malignant cancer cell. Epigenetic
alterations in cancer include changes in chromatin struc-
ture and in methylation of cytosine residues in the DNA
[1]. In comparison with normal cells, the cancer cell
genome is hypomethylated which leads to genomic insta-
bility through the activation of mobile genetic elements
[2]. Concurrently, CpG-rich regions located in many gene
promoters may become hypermethylated. The hyper-
methylation of these 5'-CpG islands may cause transcrip-
tional silencing of genes, including tumor suppressor
genes [3]. Indeed, promoter hypermethylation often acts
as second hit in the inactivation of tumor suppressor
genes, e.g. when the first allele is deleted [4].
The causes of aberrant DNA methylation in cancer are not
fully understood. There are hints that overexpression of
DNA methyltransferases (DNMTs) may be involved, such
as aberrant activity of DNMT3b promoted de novo methyl-
ation [5]. Moreover, higher levels of DNMT1 mRNA have
been detected in colorectal and stomach cancers as com-
pared to the corresponding non-neoplastic mucosa [6].
Recently, a model has been proposed to explain the phe-
nomenon why some genes become methylated during
carcinogenesis while others do not. A targeting mecha-
nism may predispose genes that are repressed by poly-
comb proteins in normal cells to aberrant DNA
methylation in cancer [7,8].
In many tumors, DNA methylation changes tend to accu-
mulate with tumor progression [9]. The profiling of
diverse cancer specimens has shown that each tumor type
bears a specific DNA methylation pattern. Such a pattern
may be used for diagnostic or prognostic purposes [10].
Moreover, aberrant DNA methylation patterns in cancer
have been used for the discovery of candidate tumor sup-
pressor genes; e.g. the HIC-1 (hypermethylated in cancer)
gene was identified on chromosomal band 17p13.3,
which had been described to be aberrantly methylated
[11]. Subsequently, the role of HIC-1 in carcinogenesis as
a transcriptional repressor has been elucidated [12]. A
variety of methods for the genome-wide screening of
methylation differences between tumor and normal cells
have been established [13] and many aberrantly methyl-
ated genes have been identified in different tumor types
[14]. As there are additional mechanisms of epigenetic
gene regulation, DNA methylation is sometimes not
tightly associated with transcriptional silencing [15,16].
Some genes even become repressed upon demethylation
[17]. Thus, after identification of a gene differentially
methylated in cancer versus normal tissue, its functional
role in carcinogenesis remains to be proven by additional
molecular and functional analyses.
In the course of a DNA methylation screening in sarcoma
cells using a methylated CpG island amplification cou-
pled with representational difference analysis (MCA-
RDA) approach, we identified the ECRG4 gene at 2q12.2
as a gene showing aberrant promoter methylation in
tumor but not in normal cells. Previous studies reported
on promoter hypermethylation and reduced expression of
ECRG4 in advanced esophageal and prostate carcinomas
[18,19] and on a tumor suppressor function of ECRG4 in
eosophageal cancer cell lines [20]. Here, we report on a
further molecular and functional characterization of
ECRG4 as a potential tumor suppressor gene in different
types of cancer.
Methods
Tumor tissue samples
Thirty-one tissue samples of colorectal carcinoma and
neighboring normal muscosa were analyzed. All patients
and control donors provided their informed oral and writ-
ten consent. Tumors were diagnosed and surgically
removed in the Knappschaftskrankenhaus Bochum-Lan-
gendreer, the Universitätsklinik Bergmannsheil Bochum
or the Katholisches Krankenhaus Dortmund-West
between 1998 and 2003. The surgically removed tumors
were classified according to the TNM/UICC system [21].
Seventy-one human glioma tissue samples, including 16
diffuse astrocytomas WHO grade II (A), 15 anaplastic
astrocytomas WHO grade III (AA), 10 secondary and 30
primary glioblastomas WHO grade IV (sGBM and
pGBM), were collected at the Department of Neuropa-
thology, Heinrich-Heine-University, Düsseldorf. All sam-
ples were analyzed in an anonymized manner as
approved by the local institutional review boards. Histo-
logical classification was performed according to the
WHO classification of tumors of the nervous system [22].
As non-neoplastic reference tissue, we used commercially
available adult human brain DNA (BD Biosciences, St.
Jose, USA) as well as DNA extracted from a cerebral tissue
sample of one adult patient who was operated on for a
non-neoplastic lesion.
Methylated CpG island amplification coupled with 
representational difference analysis (MCA-RDA)
MCA-RDA was carried out according to Toyota et al. [14].
Pooled tumor DNA from three male patients with G3
myxoid-round cell liposarcoma (round cell component >
60%) was used as tester DNA. Pooled genomic DNA from
fat tissue of three male patients with non-neoplastic dis-
ease was used as driver DNA. Briefly, 5 μg of driver and
tester DNA were sequentially digested with SmaI and
XmaI. Following adapter ligation, both samples were PCR
amplified using FastStart Taq DNA Polymerase (Roche,
Mannheim, Germany). Adapter sequences were thenBMC Cancer 2009, 9:447 http://www.biomedcentral.com/1471-2407/9/447
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removed from the driver and tester amplicon. New
adapter sequences were ligated only on the tester ampli-
con. After two rounds of competitive hybridization and
selective amplification, the MCA products were cloned
into the pDrive vector (Qiagen, Hilden, Germany). Next,
193 clones were amplified by PCR and analyzed by dot-
blot hybridization using an Alu probe. Non-Alu hybridiz-
ing inserts were sequenced and mapped onto the human
genome using BLAT and BLAST [23,24]. Amongst others,
a fragment of the ECRG4 gene, corresponding to a part of
intron 1 was cloned (Chr. 2:106682377-106682546;
UCSC genome browser, February 2009 built). The
genomic region of the ECRG4 gene including 1000 bp
upstream of the transcription start site was analyzed for its
CpG content using Methprimer [25] and a 413 bp CpG
island was identified.
Cell culture
Eleven tumor cell lines from various tissues (Tab. 1) were
obtained from American Type Culture Collection (ATCC,
Manassas, USA) and cultured according to standard pro-
tocols. To reverse methylation of the ECRG4 promoter,
cell lines were treated with 0 to 10 μM 5-aza-2'-deoxycyti-
dine (AZA) for three to four days. In addition, trichostatin
A (TSA) treatment was carried out alone or in combina-
tion with AZA treatment at a concentration of 1 μM for 24
h. AZA and TSA were purchased from Sigma (Munich,
Germany).
DNA isolation and sodium bisulfite modification
DNA from fresh frozen colorectal tumor tissue samples
and from cell lines was isolated with the QIAamp DNA
Mini Kit (Qiagen). DNA from glioma tissue samples was
extracted by ultracentrifugation over caesium chloride as
reported elsewhere [26]. Methylated control DNA was
prepared by treatment of human lymphocyte DNA with
M. SssI methylase (New England Biolabs, Ipswich, USA).
Bisulfite modification of DNA was carried out with the EZ
DNA Methylation-Gold Kit (Zymo Research, Orange,
USA) according to the manufacturer's instructions.
Methylation analysis of the ECRG4 promoter region
The  ECRG4  promoter region contains a 5'-CpG island
covering the promoter region, exon 1 and parts of intron
1 (Fig. 1a). Methylation of an upstream (-353/-136 rela-
tive to transcription start site) and a downstream (-69/
+187 relative to transcription start site) fragment from this
CpG island was determined by COBRA (combined
bisulfite and restriction analysis). Unless otherwise stated,
all PCR reactions were performed using 1.5 mM MgCl2,
0.2 mM of each dNTP, 0.3 μM of each primer and 0.5
units HotStarTaq DNA polymerase (Qiagen). Following
an initial denaturation step for 15 min at 95°C, cycling
conditions were 40 cycles for 30 s at 95°C, 30 s at the
specified annealing temperature (Ta) and 30 s at 72°C;
followed by a final 10 min elongation step at 72°C. The
upstream promoter region was amplified from sodium
bisulfite treated DNA using primers -353: 5'-AGT-
GGGGGAGTTAAGGAGATATTTT-3' and -136: 5'-
CTAAACTCCAAAACCAAAAATACTTAA-3' at a Ta of 63°C.
The resulting 217 bp product was digested into a 56 bp
and a 161 bp product by incubation with BstUI. The
downstream promoter region was amplified using prim-
ers -69: 5'-GTAGT(C/T)GTTTGGTTTTTAGTTTTT-3' and
+187: 5'-CTAAACCCCAACACAAAAACAAA-3' yielding a
256 bp product which was digested with TaqI resulting in
a 118 bp and a 138 bp product. Digestion products were
separated by polyacrylamide gel electrophoresis (8%) and
visualized by ethidium bromide staining. COBRA analysis
was carried out at least in duplicate.
PCR products (upstream fragment) obtained from
sodium bisulfite-modified DNA of selected cell lines were
cloned into the pDrive vector (Qiagen) and ten individual
clones were sequenced. The sequences were analyzed
using the BiQ Analyzer program [27]; conversion rates
were found to be between 96% and 100%.
PCR products (downstream fragment) amplified from
sodium bisulfite-modified of selected tumor samples
were purified and methylation percentages were deter-
mined by Epitect sequencing (Qiagen). The Epitect
sequencing service includes sequencing of the PCR prod-
ucts using cycle sequencing and modified analysis of raw
Table 1: Cancer cell lines analyzed for ECRG4 hypermethylation 
and expression
cell line tumor type
A549 lung carcinoma [36]
HCT116 colorectal carcinoma [37]
HeLa cervical adenocarcinoma
HepG2 hepatocellular carcinoma [38]
HT-29 colorectal adenocarcinoma [39]
HT1080 fibrosarcoma [40]
MCF7 breast adenocarcinoma [41]
SW480 colorectal adenocarcinoma [42]
U87-MG glioblastoma [43]
U373-MG glioblastoma [43]
T98G glioblastoma [44]BMC Cancer 2009, 9:447 http://www.biomedcentral.com/1471-2407/9/447
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data to obtain a percentage of methylation for each CpG
dinucleotide. Nineteen CpG sites in the promoter frag-
ment were successfully analyzed; the methylation percent-
ages of these sites were averaged to obtain a single
methylation score for each sample. Samples with a meth-
ylation score three times higher than normal colon tissue
were considered as being methylated. As the four analyzed
normal colon samples showed an averaged methylation
score of 3.7% a methylation score higher than 11.1% was
considered as being methylated.
Analysis of ECRG4 expression by reverse transcription PCR
RNA from fresh frozen colorectal tumor tissues and cell
lines was isolated using the NucleoSpin RNA II Kit (Mach-
erey-Nagel, Düren, Germany). One microgram of RNA
was reverse transcribed using the Revert Aid H-Minus M-
Mulv RT Kit (Fermentas, Vilnius, Lithuania). In the cell
lines, a fragment of the ECRG4 cDNA spanning all exons
was amplified using primers ECRG4_RT_ for: 5'-GGT-
TCTCCCTCGCAGCACCT-3' and ECRG4_RT_rev: 5'-
CAGCGTGTGGCAAGTCATGGTTAGT-3' at a Ta of 61°C
(527 bp). As this long fragment was difficult to obtain in
tumor samples, a shorter fragment of ECRG4 was ampli-
fied using forward primer ECRG4_RT_for2: 5'-GGTAC-
CAGCAGTTTCTCTACATG-3' and the reverse primer
stated above at a Ta of 62°C (220 bp). As internal control,
a 156 bp fragment of the β-actin gene was amplified using
primers ACTIN_RT_for: 5'-TCATGAAGTGTGACGTGGA-
CATC-3' and ACTIN_RT_rev: 5'-CAGGAGGAGCAAT-
GATCTTGATCT-3' at a Ta of 60°C. For semiquantitative
expression analysis, the ECRG4 RT-PCR was carried out
for 33 cycles and the β-actin RT-PCR for 26 cycles. PCR
products were separated on a 2% agarose gel and visual-
ized by ethidium bromide staining. Band intensities (BI)
were quantified using the AIDA image analyzer program
(Raytest, Straubenhardt, Germany) and relative expres-
sion levels were calculated as BI(ECRG4)/BI(β-actin).
Cloning of ECRG4 constructs
The complete ECRG4 coding region was cloned into the
pCI Neo vector (Promega, Madison, USA) for transient
transfection of cancer cell lines. The coding region was
amplified from cDNA of AZA-treated HCT116 cells using
primers 5'-gctagCATGGCTGCCTCCCCCGC-3' and 5'-
tctagaTTAGTAGTCATCGTAGTTGACGC-3' which contain
restriction site tags for NheI and XbaI, respectively (typed
in lower letters). The ECRG4  coding region was also
cloned into the peGFP-N1 vector (Clontech, Mountain
View, USA) with primers 5'-gctagCATGGCTGCCTC-
CCCCGC-3' and 5'-gctagcATGCTTCAAAAACGAGAAG-
CACC-3' which contain restriction site tags for NheI and
HindIII, respectively. As controls, cells were transfected
with the empty vectors.
Production of ECRG4 containing medium
For the production of ECRG4 or ECRG4-eGFP containing
medium, 2 × 106 HCT116 cells were plated in 10 cm
dishes. The next day, cells were transiently transfected
with the ECRG4-pCI Neo or ECRG4-eGFP and control
vectors, respectively, using 15 μl Attractene (Qiagen) and
4 μg of plasmid DNA. After twenty-four hours, the cell cul-
ture medium was replaced with fresh medium without
additives. Again twenty-four hours later, the cell culture
medium was collected and "Complete" protease inhibitor
cocktail (Roche) was added. Cellular debris was removed
by centrifugation at 700 g and the medium was concen-
trated using Amicon-15 centrifugal filter units (Millipore,
Billerica, USA). Concentrated medium was used directly
or was stored at 4°C.
ECRG4 promoter methylation and expression in different  cancer cell lines Figure 1
ECRG4 promoter methylation and expression in dif-
ferent cancer cell lines. a) Schematic representation of 
the 5'-CpG island located in the ECRG4 promoter region and 
covering exon 1 as well as parts of intron 1. Primer binding 
sites are indicated by arrows and labeled with numbers. The 
transcription start site is marked with +1; the first exon is 
represented by the grey box. b) COBRA analysis of ECRG4 
promoter methylation in various cancer cell lines. The arrow 
indicates the fragments corresponding to the methylated 
sequence. c) Re-expression of ECRG4 in SW480 and 
HCT116 cells following treatment with AZA at different con-
centrations, either alone or in combination with TSA as indi-
cated in the figure.
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Cell proliferation assays
Cell growth and viability were evaluated by using BrdU
and MTT assays, respectively. For the BrdU assay, 6 × 104
HCT116 or SW480 cells were plated in quadruplicate in
96-well plates. The next day, ECRG4-pCI Neo and control
plasmids were transfected using 0.75 μl Attractene (Qia-
gen) and 0.2 μg of plasmid DNA. Forty-eight hours post
transfection, the BrdU assay (BrdU cell proliferation
ELISA; Roche) was carried out according to the manufac-
turer's instructions. For the MTT assay, cells were plated
and transfected as described above. Forty-eight hours post
transfection, MTT solution (5 mg/ml 3-(4,5-Dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide in PBS) was
added and cells were incubated for 2 h at 37°C. Then 0.04
N HCl in 2-propanol was added and, after 45 min, the
absorption was measured photometrically at 550 nm with
a background subtraction at 690 nm. For both assays, the
mean absorbance values of at least three independent
experiments were used for statistical analysis.
The MTT assay was also carried out after treatment of cells
with ECRG4 containing medium and medium from cells
transfected with pCI Neo. Therefore, the cells were plated
as described. The next day, the cell culture medium was
removed and 50 μl of ECRG4 containing medium was
added. After 48 hours, the MTT assay was carried out as
described.
Western blot analysis
For the detection of the ECRG4-eGFP fusion protein, cel-
lular extracts or medium proteins were separated on a
20% SDS-polyacrylamide gel and blotted. Immunodetec-
tion was carried out using an eGFP antibody (Abcam,
Cambridge, UK) after over night incubation at a dilution
of 1:2000 in TBS with 0.1% Tween 20 and 5% skimmed
milk powder.
Fluorescence microscopy
For cellular localization of ECRG4-eGFP fusion proteins,
cells were grown on cover slips, transiently transfected
with the ECRG4-peGFP-N1 or control vectors using 1.5 μl
Attractene (Qiagen) and 0.4 μg of plasmid DNA. Beta-1,4-
galactosyltransferase (GalT), a Golgi resident protein, was
used as Golgi marker. Therefore, a GalT-GFP construct was
transfected as described. Forty-eight hours after transfec-
tion, cells were counterstained with DAPI and analyzed by
fluorescence microscopy at 400-fold magnification.
Statistical analysis
Statistical calculations were carried out with the GraphPad
QuickCalcs online calculator http://www.graphpad.com/
quickcalcs and STATISTICA 8 software (StatSoft, Ham-
burg, Germany). A p-value of less than 0.05 was consid-
ered as indicating statistical significance.
Results
To identify newly hypermethylated genes in cancer, we
performed a methylated CpG island amplification cou-
pled with representational difference analysis (MCA-
RDA) approach, slightly modified to Toyota et al. [14],
using soft tissue sarcoma and control tissues (data not
shown). Among several candidate sequences, a fragment
of the ECRG4 promoter was cloned.
ECRG4 promoter methylation and expression in tumor cell 
lines
To elucidate the role of ECRG4  hypermethylation in
human tumor cells, we analyzed the methylation of its
promoter in eleven cancer cell lines from colorectal, lung,
cervix, hepatocellular and breast carcinoma, fibrosarcoma
and glioblastoma (Table 1). COBRA analysis of the
upstream promoter fragment showed either full or partial
methylation in all cell lines. To confirm these results,
sodium bisulfite sequencing of PCR products from
HCT116 and SW480 cells was carried out and also
showed dense promoter methylation in both colorectal
carcinoma lines (data not shown). However, we won-
dered if the methylation of the ECRG4 promoter extends
further downstream towards the transcription start site.
We therefore analyzed a second promoter fragment by
COBRA and found that all three colorectal carcinoma and
all three glioblastoma cell lines, as well as HepG2 and
MCF7 were methylated whereas A549, HeLa and HT1080
were not (Fig. 1b).
We analyzed the panel of tumor cell lines for expression
of ECRG4 using RT-PCR. In these analyses, the ECRG4
transcript was not detected even after 40 cycles of amplifi-
cation. ECRG4 was re-expressed in the colon cancer cell
lines SW480, HCT116, HT-29 and the fibrosarcoma cell
line HT1080 after treatment with the demethylating agent
AZA. Treatment with TSA alone had no effect. Combined
treatment with AZA and TSA induced strong expression
(Fig. 1c and data not shown).
ECRG4 promoter methylation and expression in colon 
carcinoma
As the three analyzed colon cancer cell lines showed
ECRG4  hypermethylation, we asked whether ECRG4
methylation also can be found in primary colorectal
tumors. We therefore analyzed 31 samples from colon
carcinoma and 10 corresponding normal tissues by
COBRA (downstream fragment). While tumor samples
showed a high methylation frequency (19 of 31; 61%),
control tissues lacked detectable methylation (0/10; 0%)
(Fisher's exact test; p = 0.023) (Fig. 2a). Results of selected
samples were validated using the Epitect Sequencing Serv-
ice (Qiagen). Eight methylated samples displayed methyl-
ation levels ranging from 15% to 79%, sevenBMC Cancer 2009, 9:447 http://www.biomedcentral.com/1471-2407/9/447
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unmethylated samples showed methylation levels rang-
ing from 2% to 8% and four normal colon tissues showed
methylation levels of 3% to 5% (Fig. 2b). Thus, qualita-
tive and semiquantitative methylation analysis revealed a
significantly higher methylation frequency in colon carci-
noma as compared to neighboring colorectal mucosa
(unpaired t-test; p = 0.0166). To determine if ECRG4 pro-
moter methylation is correlated to gene expression, we
analyzed relative expression levels of ECRG4  by semi-
quantitative RT-PCR in eight tumor and nine normal tis-
sues. Of the eight tumor tissues, six were hypermethylated
and two were of unknown methylation status. We found
significantly lower expression of ECRG4 in tumor tissues
as compared to control tissue (BI = 0.33 vs. BI = 1.44;
unpaired t-test; p = 0.0018) (Fig. 2c).
ECRG4 promoter methylation in glioma
Next, we analyzed 71 glioma samples for methylation of
the ECRG4 promoter by COBRA. Seven out of 31 diffuse
or anaplastic astrocytomas (23%), 12 out of 30 primary
(40%) and 9 out of 10 secondary (90%) glioblastomas
carried a methylated ECRG4 promoter (Fig. 3). In con-
trast, the two investigated normal brain samples lacked
ECRG4  promoter methylation. Statistical analysis
revealed that ECRG4 methylation was significantly more
frequent in secondary glioblastomas as compared to dif-
fuse and anaplastic astrocytomas or primary glioblasto-
mas (Fisher's exact test; p = 0.0003 and p = 0.0094,
respectively).
Effect of ECRG4 protein on colorectal carcinoma cell 
proliferation
To evaluate the cellular effects of re-expression of ECRG4,
we cloned the ECRG4 coding region and transiently trans-
fected the gene into the colorectal carcinoma cell lines
HCT116 and SW480. The proliferation rate of ECRG4
transfected HCT116 cells, as assessed by the BrdU assay,
was significantly reduced to 33% (± 13%; one sample t-
test; p = 0.0133) relative to the mock-transfected control
cells (Fig. 4a). In the MTT assay, relative cell viability of
ECRG4 transfected HCT116 and SW480 cells was signifi-
cantly reduced to 33% (± 9%; one sample t-test; p =
0.0005) and 74% (± 1%; one sample t-test; p = 0.0003)
(Fig. 4b), respectively. To eliminate the influence of the
transfection on tumor cell growth, we measured cell via-
bility after treatment of cells with ECRG4 containing
medium and medium from transfection with pCI Neo.
Again, ECRG4 treated HCT116 and SW480 cells showed a
reduced cell viability relative to control treated cells (60%
± 18%; one sample t-test; p = 0.0603) (54% ± 16%; one
sample t-test; p = 0.0397) (Fig. 4c). Thus, re-expression of
the silenced ECRG4 gene as well as treatment of cells with
ECRG4 protein significantly reduced colon cancer cell
growth.
Localization of ECRG4 in cultured colorectal carcinoma 
cells
Finally, we analyzed the subcellular localization of the
ECRG4 protein and its possible secretion into the culture
medium. Therefore, we transfected an ECRG4-eGFP
fusion gene into HCT116 cells. The cell culture medium
was collected 48 h post-transfection and concentrated.
Western Blotting with an eGFP antibody detected the
ECRG4-eGFP fusion protein as three distinct bands of ~40
kDa, ~35 kDa and ~28 kDa (Fig. 5a). The highest molec-
ular weight (MW) band would fit to the MW of the
ECRG4-eGFP fusion protein (eGFP: 26 kDa + ECRG4
without signal peptide: 14 kDa). The lower MW bands
presumably represented ECRG4-eGFP proteins with N-
terminally processed ECRG4.
We also analyzed the intracellular localization of ECRG4
by fluorescence microscopy after transfection of the
fusion gene. Whereas cells transfected with the eGFP vec-
tor control showed homogenous staining all over the cell,
the ECRG4-eGFP transfected cells displayed discrete stain-
ing localized in close proximity to the nucleus (Fig. 5b).
This staining pattern was also obtained after transfection
of cells with a GFP tagged construct of the golgi resident
protein β-1,4-galactosyltransferase. Thus, it could be con-
cluded that ECRG4 was localized to the Golgi apparatus
which would be in accordance with the secretory pathway
of proteins.
Discussion and Conclusions
The data reported in this study implicate ECRG4 as a can-
didate tumor suppressor gene at 2q12.2 that is frequently
hypermethylated and transcriptionally down-regulated in
colon carcinomas and other types of human cancers. Can-
cer cells are characterized by extensive epigenetic DNA
alterations, including global hypomethylation as well as
focal hypermethylation at CpG islands in gene promoters.
DNA hypermethylation constitutes a major cause of aber-
rant gene silencing in cancer [28]. However, not all aber-
rantly silenced genes also play functional roles in tumor
development. In analogy to somatic mutations in tumor
cells, which in part are neutral passenger mutations, some
methylation events might be epigenetic passengers [29].
Therefore, each candidate tumor suppressor gene identi-
fied by methylation screening methods has to be carefully
evaluated for its role in tumor development and progres-
sion.
In the course of a methylation screening approach, we
identified ECRG4 as a gene differentially methylated in
sarcoma versus normal cells. Previously, ECRG4 had been
found to be hypermethylated in esophageal cancer [30].
To investigate its possible role in human cancer, we (1)
analyzed different tumor entities for ECRG4  promoterBMC Cancer 2009, 9:447 http://www.biomedcentral.com/1471-2407/9/447
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methylation, (2) revealed a correlation between the meth-
ylation and gene silencing, (3) measured the effect of
ECRG4 re-expression on the proliferation of colon cancer
cells, and (4) determined the cellular localization of the
ECRG4 protein.
Initially, we found the ECRG4 promoter to be frequently
hypermethylated in a broad spectrum of human tumor
cell lines. To exclude that hypermethylation is limited to
tumor cells in culture we carried out qualitative and sem-
iquantitative methylation analysis of primary cancer sam-
ples. In colorectal carcinomas, we found a high frequency
of methylation, but, as the analyzed samples were all from
advanced staged tumors, correlations to clinical features
were not possible. We also found frequent methylation in
astrocytic gliomas, in which the methylation frequency
ECRG4 promoter methylation and mRNA expression in primary colorectal carcinoma samples Figure 2
ECRG4 promoter methylation and mRNA expression in primary colorectal carcinoma samples. a) COBRA anal-
ysis of ECRG4 methylation in colorectal carcinoma and normal colon tissue samples. Arrows point to restriction fragments 
indicating a methylated sequence. b) Box plots of methylation percentages of selected colorectal carcinomas and normal colon 
tissue as determined by Epitect bisulfite sequencing analysis. unmeth = unmethylated; meth = methylated c) Box plots of rela-
tive ECRG4 mRNA expression as determined by semiquantitative RT-PCR in colorectal carcinomas relative to normal colon 
tissue. Note a significantly lower expression in tumor tissue (p = 0.0018). NT = normal colon tissue; CC = colorectal carci-
noma.BMC Cancer 2009, 9:447 http://www.biomedcentral.com/1471-2407/9/447
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increased with advancing tumor grade, being particularly
common in glioblastomas. This result is consistent with
recent reports that ECRG4 methylation is associated with
advanced disease and poor prognosis in esophageal and
prostate cancer patients [18,31]. Our findings of frequent
ECRG4 methylation in various cancer cell lines may sug-
gest that ECRG4 might be methylated in even other tumor
types. Hence, ECRG4 might belong to the set of genes that
are frequently methylated in multiple types of cancer.
Another example is the pro-apoptotic gene RASSF1A,
which is rarely mutated but often hypermethylated in var-
ious kinds of epithelial, mesenchymal and neuroectoder-
mal tumors [32]. Such genes often regulate processes that
are crucial for cancer development, such as apoptosis or
cell cycle progression.
Our data also indicate that ECRG4 promoter methylation
strongly correlates with transcriptional silencing. None of
the methylated cancer cell lines showed expression of
ECRG4 transcripts. Furthermore, the expression level of
ECRG4 promoter methylation in primary glioma tissue samples Figure 3
ECRG4 promoter methylation in primary glioma tissue samples. COBRA analysis of ECRG4 methylation in astrocytic 
gliomas of different WHO grades and two non-neoplastic brain samples (NB1, NB2). Representative data from 49 samples are 
shown. Arrows point to restriction fragments indicating a methylated sequence. The diagnosis is given in the subheadings. The 
tumor numbers are provided on top of each lane.BMC Cancer 2009, 9:447 http://www.biomedcentral.com/1471-2407/9/447
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ECRG4 was significantly lower in colon cancer samples
than in normal mucosa, which agrees with the recent
result that ECRG4 expression is lower in esophageal can-
cer than in surrounding normal epithelium [19]. It should
be noted that two normal colon tissues also showed weak
ECRG4 expression. This could be due to a methylation
field effect in normal tissue surrounding tumor tissue.
Alternatively, it cannot be ruled out that ECRG4 silencing
might be regulated by other mechanisms than DNA meth-
ylation. Then again, ECRG4 expression could be reacti-
vated by demethylating treatment, which is a known
feature of epigenetically silenced tumor suppressor genes
[33,34].
By ECRG4 overexpression or ECRG4 treatment, we dem-
onstrate an inhibitory effect of this protein on colorectal
carcinoma cell growth. Using two independent assays of
cell viability and cell proliferation, we found reduced
growth rates after ECRG4 transfection or culturing of cells
in ECRG4 containing medium. An additional hint sup-
porting a growth suppressive effect of ECRG4 in tumor
cells comes from stabile transfection experiments, in
Effects of ECRG4 overexpression or ECRG4 treatment in colorectal carcinoma cells on proliferation and viability Figure 4
Effects of ECRG4 overexpression or ECRG4 treatment in colorectal carcinoma cells on proliferation and viabil-
ity. a) Reduced proliferation rate of ECRG4 transfected HCT116 and SW480 cells relative to control cells as determined by the 
BrdU assay (n = 3; p = 0.0133) (n = 3; p = 0.0775). b) Reduced cell viability of ECRG4 transfected HCT116 and SW480 cells rel-
ative to control cells as determined by the MTT assay (n = 4; p = 0.0005) (n = 3; p = 0.0003). c) Reduced cell viability of 
HCT116 and SW480 cells treated with ECRG4-containing medium relative to cells treated with medium from pCI Neo trans-
fection as determined by the MTT assay (n = 3; p = 0.0603) (n = 3; p = 0.0397).
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Extracellular secretion and subcellular localization of the ECRG4 protein Figure 5
Extracellular secretion and subcellular localization of the ECRG4 protein. a) Western Blot analysis with an anti-GFP 
antibody of concentrated cell culture medium of ECRG4-eGFP transfected HCT116 cells shows that ECRG4 is secreted. 1 = 
concentrated medium of non-transfected cells; 2 = total lysate of eGFP transfected cells; 3 = concentrated medium of ECRG4-
eGFP transfected cells. Arrows point to three different processed forms of the ECRG4-eGFP fusion protein. b) Fluorescence 
microscopy analysis of HCT116 cells transfected with eGFP, ECRG4-eGFP and GalT-GFP vectors. Note that transfection with 
the eGFP control vector leads to homogenous staining, whereas cells transfected with the ECRG4 fusion gene show staining of 
discrete structures. These structures are also stained after transfection of the GFP tagged Golgi marker galactosyltransferase 
(GalT-GFP).
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which we observed that the expression of the transgene
rapidly declined, presumably by de novo methylation
(data not shown). Recent findings show that ECRG4 acts
as a tumor suppressor in esophageal cancer cells in vitro
and in vivo [20]. Our data provide first hints that ECRG4
may serve a tumor suppressor function also in colorectal
carcinoma cells.
Finally, we demonstrate that ECRG4 is a secreted protein.
The ECRG4 gene codes for a small protein of 148 aa (17
kDa) of yet unknown function and without significant
homology to other known proteins, except for a 31%
homology to the mouse IgG V region [19]. A putative N-
terminal signal peptide suggests that ECRG4 might be a
secreted protein. We found that an ECRG4-eGFP fusion
protein localized to the Golgi apparatus within the cell,
which would be consistent with the secretory pathway of
proteins. In addition, we detected the ECRG4-eGFP fusion
protein in the cell culture medium of transfected cells.
Recently, the ECRG4 protein was renamed in the Uniprot
database http://www.uniprot.org as "augurin", a protein
which had been identified in a bioinformatics approach
as a putative new peptide hormone [35]. Mirabeau et al.
showed that augurin is a secreted protein which is proc-
essed from its prepro-form. However, only limited
augurin expression was found in murine endocrine tis-
sues. In addition to its potential expression in endocrine
glands, ECRG4 is expressed in normal epithelium of the
colon and esophagus and in fat tissue as shown here and
in other studies [18,19]. The findings of Mirabeau et al.
(2007) support the hypothesis that ECRG4 functions as
an extracellular signaling molecule. Interestingly, unlike
other peptide hormones, the signaling of ECRG4 is not
growth promoting but rather growth limiting.
In conclusion, we show that the ECRG4 gene is frequently
hypermethylated in a variety of human cancer cells.
Hypermethylation associates strongly with transcriptional
silencing in colorectal carcinomas. Furthermore, ECRG4
displays growth-inhibitory effects on colon cancer cells in
vitro and may function as a secreted extracellular signaling
molecule. Thus, restoring ECRG4 expression in the tumor,
either by epigenetic therapy or application of recom-
binant protein, may represent a promising novel thera-
peutic approach in various types of cancers.
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